MPE comments on the European Medicines Agency’s policy on the handling of competing interests of scientific committees’ members and expertsMPE, NewsNovember 14, 2024
MPE comments on the Implementing Regulation on joint scientific consultations on medicinal products for human use at Union levelAccess, latest, NewsOctober 29, 2024
Watch the webinar “Importance of good nutrition and healthy diet for young myeloma patients”Myeloma, VideosOctober 18, 2024
During European Myeloma Day, MPE highlights the importance of improving access to clinical trialsAccess, MPE, MyelomaSeptember 27, 2024
EMA recommends a new indication for daratumumab in adult patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantAccess, MyelomaSeptember 26, 2024
A second bispecific antibody is approved as a fourth-line treatment for myeloma in England and WalesAccess, latest, Myeloma, NewsJuly 17, 2024
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and WalesAccess, latest, MyelomaJuly 9, 2024
MPE comments on the second implementing act of the EU health technology assessment (HTA) regulation (EU HTAR)Access, MPEJune 26, 2024
